Postpartum Hemorrhage Devices Market Size & Share, by Product Type (Uterine Balloon Tamponade, Non-Pneumatic Anti-Shock Garment, Uniject Prefilled Injection System, Vacuum Induced Hemorrhage Control Devices); Condition; Patient Type; End user; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Postpartum Hemorrhage Devices Market - Regional Analysis

North America Market Insights

North America is predicted to capture the highest share of 35.6% in the global PPH devices market during the analyzed tenure. The presence of advanced medical facilities and a high density of childbirths in hospitals facilitates the region's dominance in this sector. Besides, comprehensive reimbursement frameworks and robust federal investments are collectively minimizing the financial barriers to accessing PPH treatments, which ultimately enhances the cash inflow in this sector. As evidence, in 2025, the American Hospital Association (AHA) unveiled that Medicaid was covering for over 40% of births in the U.S., including nearly 50% of births in rural communities. The report also identified this backing as the vital source of prenatal and postpartum care for women across the country.

The U.S. is augmenting the postpartum hemorrhage devices market with the enlarging patient pool and technological advancements. The regulatory and clinical authorities in the country also provide immense support by enabling accelerated clearances. Exemplifying the same, in September 2023, the American College of Obstetrics and Gynecology (ACOG) released promising outcomes from the RUBY study, evaluating the efficacy of the JADA System. It analyzed the user experience of the product, collected 800 eligible candidates from 16 hospitals in the U.S. and unveiled that the time to control bleeding to be just 5 minutes in 73.8% of vaginal births.

In Canada, the postpartum hemorrhage devices market is gaining momentum, particularly following the approval of the JADA System in February 2024, as testified by the press release of Organon. This vacuum-based tamponade device introduced a novel, conservative treatment option for PPH, which aligns perfectly with the increasing and evolving needs. Moreover, the country's efforts to secure optimum maternal safety and convenience are escalating the scale of infrastructural reinforcement in Canada, where the enhanced outcomes from PPH management with devices are propelling adoption in this sector.

APAC Market Insights

Asia Pacific is expected to become the fastest-growing region in the global postpartum hemorrhage devices market by the end of 2035. This robust pace of propagation originates from the rising maternal mortality due to prevalent complications, such as multiple pregnancies and inverted uterus. The demography can also be testified by the WHO report, underscoring Southern Asia as the source of 17% of global maternal deaths in 2023. This is heightening the demand for advanced obstetric equipment and hence, fueling this sector. Governments across the region are also contributing to the sector's continuous expansion by investing more heavily in dedicated healthcare infrastructure and awareness.

China is maintaining a strong position in the APAC PPH devices market on account of its large patient population and government-led healthcare reinforcement programs. In this regard, the 2025 NLM report unveiled that the incidence rate of PPH in this country ranges between 2.88% and 15.4%. Furthermore, supportive government initiatives include the partnership formation between the Government of China and UNICEF in February 2025, which was aimed at improving maternal and child health. These systemic enhancements in maternity care provision are consolidating the nation's position in this sector.

Despite the significant reduction in maternal mortality rate (MMR) in India, PPH remains a pressing public health concern, especially in high-burden states. Thus, the governing body of the country continues to invest in the postpartum hemorrhage devices market through initiatives such as Janani Shishu Suraksha Karyakaram (JSSK). Moreover, the leveraged volume of community service networks, including the ASHAs under the National Health Mission (NHM), is improving institutional deliveries and early PPH management, which ultimately benefits the landscape.

Country-wise Government Efforts Benefiting the Market

Source: ACT Government, NHMS 2022, and Korea Institute of Child Care and Education

Europe Market Insights

Europe is poised to showcase steady growth in the postpartum hemorrhage devices market while consolidating its position as the second-largest shareholder during the timeline between 2026 and 2035. The region's augmentation in this sector is highly attributed to targeted government initiatives, technological innovations, and evolving regulatory frameworks. Exemplifying such a favorable atmosphere, in November 2022, Medtrade Products earned CE certification for its CELOX PPH Uterine Haemostatic Tamponade. The approval was based on the extensive clinical evaluation conducted by the Department of Obstetrics at the Charité University Hospital in Berlin, which identified the product to be highly effective in the control and treatment of uterine PPH.

Germany is a leading contributor to the Europe postpartum hemorrhage (PPH) devices market, which is backed by its robust healthcare infrastructure and MedTech innovations. The high volume of hospital deliveries also facilitates an increase in the adoption of advanced medical technologies available in this sector. Further, as a testimony of the large patient pool and value-based implementation, a real-world study was published by the European Journal of Obstetrics & Gynecology and Reproductive Biology in 2024, which demonstrated the success rate of hemorrhage termination through the Jada system across Germany to be 92.5%.

The UK plays a pivotal role in solidifying the regional progress in the postpartum hemorrhage devices market. The well-established healthcare infrastructure and national focus on maternal health are collectively empowering the country's propagation in this sector. In support of the same, the National Health Service (NHS) has implemented guidelines promoting the use of effective PPH management devices, such as UBT, to reduce maternal morbidity and mortality. Government initiatives also include investments in the development of innovative PPH devices that are designed to be used across hospitals and maternity centers.

Government Provinces in Maternity Health

Source: UNFPA and FDFA